


Imaging Protocol Case Study for Myoview

Example of the efficiencies gained when the MPI imaging protocol is updated to reflect proper Myoview imaging times

Previous Protocol vs Updated Protocol



Per the Prescribing Information for Myoview: Imaging may begin 15 minutes after injection. When rest and stress injections are administered on the same day, the first dose should be 185-444 MBq (5-12 mCi) followed by the second dose of 555-1221 MBq (15-33 mCi), given approximately one to four hours later.¹

Efficiency outcomes observed at one hospital*:



- Hospital estimated approximately 10.5 hours a week in productivity saved for one technologist
- The updated protocol did not result in any increase in rescan rates or loss of image quality
- No negative feedback from imagers or physicians following implementation of the updated protocol

2016 ASNC imaging guidelines for SPECT nuclear cardiology procedures:

*Example of the efficiencies gained at Barnes-Jewish Hospital in St. Louis, Missouri. Other facilities may experience different results. Information provided by Barnes-Jewish Hospital [2017].

MPI, myocardial perfusion imaging.

PRODUCT INDICATIONS AND USE

MYOVIEW™ (Kit for the Preparation of Technetium Tc-99m Tetrofosmin for Injection) is indicated for myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. Myoview is also indicated for the assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Risks Associated With Exercise or Pharmacologic Stress:** Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, and bronchoconstriction, as well as cerebrovascular reactions such as headache, paraesthesias, convulsions, somnolence, and cerebrovascular accident, including hemorrhage. Perform stress testing in a setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's Prescribing Information

Please see additional Important Safety Information, [here](#), and Full Prescribing Information, [here](#).



MYOVIEW™
(Kit for the Preparation of
Technetium Tc99m Tetrofosmin
for Injection)

Outcomes achieved in this case study as a result of updated protocol

“Over the last six months, our Nuclear Medicine MPI cardiac volume has increased roughly 25%, which translates to an equivalent of approximately one additional study performed per day.”

Outcomes Observed by Hospital



PATIENTS

Shortened overall test time to approximately three hours, as opposed to four hours or longer using previous protocol.



NUCLEAR TECHNOLOGISTS

Patient imaging studies are now more efficiently performed, resulting in faster processing and submission of studies. In addition, new protocol now results in technologists' ability to get to other duties sooner in the day.



RADIOLOGISTS

Now able to interpret the studies at an earlier time (compared with prior protocol).



NUCLEAR MEDICINE DEPARTMENT

Department throughput for patients is now greater as a result of shortened total test time achieved with updated protocol.



PRODUCT INDICATIONS AND USE

MYOVIEW™ (Kit for the Preparation of Technetium Tc-99m Tetrofosmin for Injection) is indicated for myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. Myoview is also indicated for the assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.



Please see additional Important Safety Information, [here](#), and Full Prescribing Information, [here](#).

MYOVIEW™
(Kit for the Preparation of
Technetium Tc99m Tetrofosmin
for Injection)

Stress, protocols, and tracers²

- For Tc-99m tetrofosmin, minimum delays of 10 to 15 minutes for exercise, 30 to 45 minutes for rest, and 45 minutes for pharmacologic stress are optimal*

*Optimal imaging times as per ASNC's published recommendations. Validation of optimal imaging times has not been extensively studied; factors such as camera availability and the presence of liver and gastrointestinal activity influence the optimal imaging times.



ASNC, American Society of Nuclear Cardiology; SPECT, single-photon emission computed tomography.

Please see Important Safety Information, [here](#), and Full Prescribing Information, [here](#), for additional important safety information.

MYOVIEW™
 (Kit for the Preparation of
 Technetium Tc99m Tetrofosmin
 for Injection)

PRODUCT INDICATIONS AND USE

MYOVIEW™ (Kit for the Preparation of Technetium Tc-99m Tetrofosmin for Injection) is indicated for myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease. Myoview is also indicated for the assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Risks Associated With Exercise or Pharmacologic Stress:** Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, and bronchoconstriction, as well as cerebrovascular reactions such as headache, paraesthesias, convulsions, somnolence, and cerebrovascular accident, including hemorrhage. Perform stress testing in a setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's Prescribing Information
- **Radiation Risks:** Technetium Tc-99m contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation reconstitution procedures to protect patients and healthcare workers from unintentional radiation exposure. Encourage adequate hydration; instruct patients to void when the examination is completed and as often thereafter as possible
- **Hypersensitivity Reactions:** Hypersensitivity reactions, including anaphylaxis, dyspnea, bronchospasm, throat tightness, coughing, tachycardia, chest pain, hypotension, abdominal pain, and cutaneous reactions (rash, urticaria, pruritus, erythema, and swelling or angioedema) have been observed after the administration of Myoview. Always have cardiopulmonary resuscitation equipment and personnel available, and monitor all patients for hypersensitivity reactions

ADVERSE REACTIONS

- Serious episodes of angina, ventricular tachycardia, and respiratory arrest were reported. Other events included angina, hypertension, torsades de pointes, vomiting, abdominal discomfort, cutaneous allergy, hypotension, dyspnea, metallic taste, burning of the mouth, and smell alteration. The following were reported when used with pharmacological stress: Angina, flushing, dyspnea, headache, abdominal pain, dizziness, palpitations, nausea, hypotension, pain, cough, arrhythmia, bronchospasm, ECG (electrocardiogram) abnormalities, hypertension, vomiting, and asthenia. Postmarketing adverse reactions included rash, urticaria, abnormal vision, hypersensitivity reactions, and fever

USE IN SPECIFIC POPULATIONS

- **Nursing Mothers:** Technetium Tc-99m tetrofosmin is present in human milk in small amounts (<1% of maternal dose). There are no data available regarding the effects of technetium Tc-99m tetrofosmin on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Myoview and any other potential adverse effects on the breastfed child from Myoview or from the underlying maternal condition. To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard for 60 hours (10 half-lives) after technetium Tc-99m tetrofosmin administration.
- **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established
- **Geriatric Use:** No overall differences in safety were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between elderly patients and younger patients, but greater sensitivity regarding some older individuals cannot be ruled out

Prior to Myoview administration, please read the Full Prescribing Information, [here](#).

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800 654 0118 (option 2, then option 1), or the FDA at 800 FDA 1088 or www.fda.gov/medwatch.

References: 1. Myoview [prescribing information]. Arlington Heights, IL: GE Healthcare; 2022.
2. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. *J Nuc Cardiol*. ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. 2016;23:606-639.

Customer Service 800 292 8514

Medical Affairs 800 654 0118 (option 2, then option 3)
or medical.affairs@ge.com

Reimbursement Hotline 800 767 6664
gehealthcare.com



MYOVIEW™
(Kit for the Preparation of
Technetium Tc99m Tetrofosmin
for Injection)